# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week check of potassium and creatinine after starting losartan and empagliflozin, home readings, and the echocardiogram. **S**

## History of present illness

Madam Walker returns two weeks after starting losartan 50 mg, empagliflozin 10 mg and atorvastatin 20 mg. She has taken them each morning at home time, including on a four-day trip. Her home readings average 144/90, down from 152/96. The morning headaches have stopped. She has had no dizziness, cough, genital itching or muscle aches, and urinates slightly more in the first hours after the empagliflozin. She had a video session with the dietitian and has made a salt-free version of her seasoning blend. Her hepatitis B, hepatitis C and HIV tests were negative, and she has no hepatitis B immunity. The echocardiogram was done this morning. She leaves next week for three weeks of conventions. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 144/90 on losartan 50 mg |
| Side effects | None |
| Diet | Dietitian session done; salt-free seasoning blend |
| Screening tests | Hepatitis B and C and HIV negative; no hepatitis B immunity |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness or fainting |
| Neurological | Negative | Morning headaches gone |
| Respiratory | Negative | No cough |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Negative | No muscle aches |

5 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet each morning **S**
- Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/92 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 78.2 kg; BMI 29.4 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 24 mmol/L; Creatinine: 1.29 mg/dL (high); eGFR (CKD-EPI 2021, race-free): 51 mL/min/1.73 m² (low). All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Bicarbonate (total CO2): 25 mmol/L at baseline, 24 mmol/L at this visit **S**
- Creatinine: 1.22 mg/dL (high) at baseline, 1.29 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 2021, race-free): 54 mL/min/1.73 m² (low) at baseline, 51 mL/min/1.73 m² (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/92, pulse 78; weight 78.2 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Respiratory | Clear |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3a A2** (N18.31). Potassium 4.6 mmol/L; creatinine 1.29 mg/dL (eGFR 51), up 7% from 1.21: the expected change after starting losartan and empagliflozin, well under the 30% that would call for review. Bicarbonate 24 mmol/L. **S**
   - Continue empagliflozin.
   - Increase losartan to 100 mg.
   - Potassium and creatinine two to four weeks after the increase.
2. **Hypertension with chronic kidney disease** (I12.9). Improving but above goal. Echocardiogram: mild concentric left ventricular hypertrophy (septum 1.2 cm), ejection fraction 60%, normal valves; this should regress as her pressure comes down. **S**
   - Losartan 100 mg each morning.
   - Home readings daily for a week, then twice a week.
   - Amlodipine next if the average stays above 130/80.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 148/92 |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Average 144/90 |
| Examination | Weight and BMI | Every visit | Completed today | 78.2 kg |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Completed today | Two weeks after starting: potassium 4.6, bicarbonate 24 mmol/L; creatinine 1.29 mg/dL, eGFR 51, a 7% rise; repeat two to four weeks after today's increase |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Up to date | 294 mg/g two weeks ago; next at about three months |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or LVH on ECG | Completed today | Mild concentric LVH; ejection fraction 60% |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Up to date | Atorvastatin started two weeks ago; panel at the next visit |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | No dizziness, cough, genital itching or muscle aches; doses taken at home time when traveling; sick-day card in her bag |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Dietitian session done; salt-free seasoning; ordering strategies for banquets |
| Laboratory | Hepatitis B, hepatitis C and HIV tests | Once, with the kidney evaluation | Completed today | All negative; no hepatitis B immunity, so vaccination is planned |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated. In progress; target 2026-08-17. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. In progress; target 2026-08-17. **S**
- Kidney function stable, without a fall in eGFR of more than 30% after starting treatment. In progress; target 2026-08-17. **S**
- Sodium under 2 g a day using foods she likes, at home and on the road. In progress; target 2026-08-17. **S**
- LDL cholesterol lower by at least 30%. In progress; target 2026-04-27. **S**
- Care that fits her work: every check scheduled around her travel, by her choice. In progress; target 2026-08-17. **S**

## Medication changes

- Stopped: Losartan 50 mg oral tablet, one tablet each morning **S**
- Started: Losartan 100 mg oral tablet, one tablet each morning **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American College of Cardiology and American Heart Association (Circulation 2019)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026), Aether Forge

## Follow-up

- Potassium and creatinine two to four weeks after the losartan increase. Review in about seven weeks with the urine albumin, kidney function and lipids. Call for dizziness, fainting, or vomiting or diarrhea (hold losartan and empagliflozin). **S**
- Next scheduled visit 2026-04-27: eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin. **S**
